Blood Res.  2014 Dec;49(4):211-213. 10.5045/br.2014.49.4.211.

The puzzle of myeloproliferative neoplasms: novel disease-specific mutations and new proposals for diagnostic criteria

• Kim HJ
• Choi CW
• Won JH

• KMID: 2270675
• DOI: http://doi.org/10.5045/br.2014.49.4.211

Abstract

No abstract available.

Reference

1. Swerdlow SH, Campo E, Harris NL, et al. WHO Classification of tumours of haematopoietic and lymphoid tissues. 4th ed. France: IARC Press;2008.

2. Tefferi A, Thiele J, Vannucchi AM, Barbui T. An overview on CALR and CSF3R mutations and a proposal for revision of WHO diagnostic criteria for myeloproliferative neoplasms. Leukemia. 2014; 28:1407–1413. PMID: 24441292.

3. Rumi E, Pietra D, Ferretti V, et al. JAK2 or CALR mutation status defines subtypes of essential thrombocythemia with substantially different clinical course and outcomes. Blood. 2014; 123:1544–1551. PMID: 24366362.

4. Tefferi A, Lasho TL, Finke C, et al. Type 1 vs type 2 calreticulin mutations in primary myelofibrosis: differences in phenotype and prognostic impact. Leukemia. 2014; 28:1568–1570. PMID: 24569778.

5. Barbui T, Thiele J, Carobbio A, et al. Discriminating between essential thrombocythemia and masked polycythemia vera in JAK2 mutated patients. Am J Hematol. 2014; 89:588–590. PMID: 24535932.

6. Barbui T, Thiele J, Vannucchi AM, Tefferi A. Rethinking the diagnostic criteria of polycythemia vera. Leukemia. 2014; 28:1191–1195. PMID: 24352199.